Aristolactam AIIIa is a new type of Plk1 inhibitors, targeting the Polo Box domain (PBD), it has anti-tumor activity. Aristolactam IIIa shows inhibition of platelet aggregation induced by collagen or arachidonic acid.
Isotetrandrine is a small molecule inhibitor, on various aspects of LPS-induced inflammation in vitro and in vivo. It dose-dependently suppresses the severity of LPS-induced ALI by inactivation of MAPK and NF-κB, which may involve the inhibition of tissue